Incyte to acquire Vega Therapeutics for $1.25B upfront; total up to $2.0B

INCYTE CORP

• Acquires Vega Therapeutics from Star Therapeutics; adds VGA039, a Phase 3 anti-Protein S mAb for von Willebrand disease.
• Star receives $1.25B upfront; up to $750M in sales milestones for total consideration of $2.0B.
• VGA039 has Breakthrough Therapy, Fast Track, and orphan drug designations from FDA; Phase 3 VIVID-6 trial ongoing.
• Transaction approved by both boards; expected to close in Q3 2026 subject to HSR review.
• Incyte expects a ~$1.25B R&D charge in Q3 and full year 2026 GAAP and non-GAAP results.